Related Experiment Video
Updated: May 29, 2026
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
PET imaging in a longitudinal non-Hodgkin's lymphoma study: association with tumor volume
Maija Rossi1, Pasi Korkola, Hannu Pertovaara
1Medical Imaging Centre, Department of Radiology, Tampere University Hospital, Tampere, Finland. maija.rossi@pshp.fi
Background:
Computed tomography (CT) is generally used in the evaluation of the treatment response of non-Hodgkin's lymphoma (NHL) patients. Instead of morphological images, positron emission tomography (PET) shows metabolic information that is connected to tumor activity, cell proliferation rate, and, thus, prognosis.
Purpose:
To determine the prognostic value of PET for tumor volume reduction measured by CT and magnetic resonance imaging (MRI) along with clinical characteristics in NHL patients.
Material And Methods:
We imaged 21 B-cell type NHL patients using whole-body 18F-FDG-PET at the onset and the completion of treatment and at six-month follow-up. The maximum standardized uptake value (SUV(max)) was calculated. Morphological tumor volume calculations were assessed using both MRI and CT. Additionally, patients underwent thorough clinical examination including several laboratory tests.
Results:
A high SUV(max) was able to predict significant tumor volume reduction at the beginning of treatment, but the relation to pure tumor volume was poor.
Conclusion:
The SUV(max) values derived from FDG-PET seemed to correlate with volume changes but not with their absolute values or laboratory tests. Unlike MRI and CT, FDG-PET showed the disappearance of active tumors after treatment.
